Drug details:
Molecular formula: C₂₆H₂₀N₄O₈S₄

Standard name: 2-[3-[(5E)-5-[3-[3-(2-carboxyanilino)-3-oxopropyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoylamino]benzoic acid

Curated SMILES: C1=CC=C(C(=C1)C(=O)O)NC(=O)CCN2C(=O)/C(=C\3/C(=O)N(C(=S)S3)CCC(=O)NC4=CC=CC=C4C(=O)O)/SC2=S

Evidence for compound's anti-virulence activity:

Brucella
Related VF: VirB type IV secretion system
Target: VirB8
Drug effect: Inhibits T4SS by targeting an essential assembly protein VirB8.
Max phase: Preclinical (in vivo)
Publication:
Paschos A, et al., 2011. An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect Immun 79(3):1033-43.